VEOZAH

Indicated For

moderate to severe vasomotor symptoms (VMS) due to menopause, hot flashes, night sweats

About This Medication

# Astellas Patient Assistance Program Patient Guide: How to Get VEOZAH (fezolinetant) at Low or No Cost VEOZAH (fezolinetant) is a prescription medication used to treat moderate to severe hot flashes (vasomotor symptoms) due to menopause in women. The **Astellas Patient Assistance Program (PAP)** provides **VEOZAH at no cost** to eligible uninsured patients in the United States who meet program criteria, with no specific income requirements listed. ## About VEOZAH (fezolinetant) **VEOZAH** is a non-hormonal treatment approved by the FDA for reducing the frequency and severity of moderate to severe vasomotor symptoms, commonly known as hot flashes and night sweats, associated with menopause. Unlike hormone replacement therapies, it works by blocking neurokinin 3 (NK3) receptors in the brain to help regulate body temperature control disrupted during menopause. It's taken as one 45 mg tablet once daily with or without food. Common side effects may include back pain, hot flashes (early in treatment), and elevated liver enzymes; always discuss risks with your doctor. This program helps make this innovative therapy accessible when cost is a barrier. ## Who Qualifies for the Astellas Patient Assistance Program? The program targets patients facing financial hardship with access to **VEOZAH**. Key eligibility factors include: - **Uninsured status**: Primarily for patients with **no insurance** coverage for the medication. Commercially insured patients should use the **Savings Program** (details via program phone). Medicare, Medicaid, or other government insurance patients should **call (866) 239-1637 for options**, as standard PAP may not apply. - **U.S. residency**: Must live in the United States. - **Income eligibility**: **No specific income thresholds** (e.g., Federal Poverty Level percentages) are mentioned; eligibility is assessed case-by-case for uninsured patients meeting other requirements. Proof of income may be requested during screening. - **Prescription requirement**: Must have a valid prescription from a U.S. healthcare provider. - **Other**: Not eligible if enrolled in government programs that cover the drug, or if insurance denies coverage but alternatives exist. | Household Size | Annual Income Limit | Notes | |---------------|---------------------|-------| | Individual | Not specified | No FPL % listed; assessed individually | | Couple | Not specified | Case-by-case for uninsured | | Family of 3 | Not specified | Proof of income may be needed | | Family of 4+ | Not specified | Call for pre-screening | *Table based on program details; no fixed limits mean broader potential access, but approval isn't guaranteed.* ## Insurance Requirements - **Uninsured patients**: Ideal candidates; certify no insurance and ineligibility for public programs. - **Commercially insured**: Use **Astellas Savings Program** for copay assistance instead. - **Medicare/Medicaid**: **Call (866) 239-1637**; may have limited options or referrals to other programs. Include front/back copies of any insurance cards on application. - **Denied coverage**: Provide denial letters if applicable, though primarily for uninsured. ## Step-by-Step Application Process Applications are **initiated by your healthcare provider** (doctor, social worker, or office staff)—**patients cannot apply directly**. 1. **Contact your provider**: Ask them to assess you for the PAP via Astellas Pharma Support Solutions. Provide your full name, DOB, address, and insurance status. 2. **Pre-screening**: Provider calls **(866) 239-1637** (or drug-specific line if available) for phone screening on eligibility (insurance, residency, income). 3. **Complete enrollment form**: Provider fills out the **Patient Enrollment Form** (sent to their office). You sign the **Patient Authorization Statement** (pages 4-6 typically), certifying info accuracy and consenting to data use for eligibility, fulfillment, and referrals. 4. **Gather documents**: Attach proof of income (e.g., tax returns, pay stubs), insurance cards (front/back), and any denial letters. No full list specified, but asterisks (*) mark required fields like name, DOB, address. 5. **Submit**: Provider faxes, mails originals, or uploads via Prescriber Portal. Multiple methods available. 6. **Approval notification**: If eligible, you'll be notified; medication ships to your home. **Tip**: Missing info delays processing—ensure completeness. ## Timeline and Delivery - **Processing time**: Not specified; decisions often during phone screening, but full review may take days to weeks. Fax/mail originals after initial fax if needed. - **Delivery**: **Shipped directly to your home** at no cost if approved. Coordinate with provider for prescription fulfillment. - **Refills/reauthorization**: Not detailed; notify of changes (insurance, income, residency). Likely annual recertification—call for status. ## Alternatives if Denied or Ineligible - **Savings Program**: For commercial insurance; reduces copays. - **Other assistance**: Program may refer to independent sources (e.g., state programs, nonprofits like RxHope, NeedyMeds). No biosimilars for VEOZAH. - **Generic options**: None available; discuss non-drug therapies (lifestyle, other meds) with your doctor. - **Appeal**: Contact (866) 239-1637 if denied; update circumstances. - **RxHope/PAN Foundation**: Search for menopause-related aid. ## Important Disclaimer This guide is for informational purposes based on available program details as of latest knowledge. **Eligibility, terms, and availability can change**—**always verify directly with Astellas at (866) 239-1637 or AstellasPharmaSupportSolutions.com**. Not legal/medical advice; consult your healthcare provider. Astellas reserves rights to modify/terminate program. By applying, you agree to notify of eligibility changes. Approval not guaranteed; false info may disqualify. Word count: ~950.

Program information last verified: March 30, 2026